Home » Stocks » BVS

Bioventus, Inc. (BVS)

Stock Price: $11.49 USD -0.48 (-4.01%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 652.92M
Revenue (ttm) 320.12M
Net Income (ttm) 19.27M
Shares Out 54.88M
EPS (ttm) 0.35
PE Ratio 32.72
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $11.49
Previous Close $11.97
Change ($) -0.48
Change (%) -4.01%
Day's Open 11.93
Day's Range 10.74 - 11.93
Day's Volume 459,636
52-Week Range 10.74 - 19.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

DURHAM, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that fourth qua...

GlobeNewswire - 3 weeks ago

Bioventus Inc. ("Bioventus" or the “Company”) today announced the pricing of its initial public offering...

Business Wire - 1 month ago

DURHAM, N.C.--Bioventus Inc. ("Bioventus" or the “Company”), today announced that it has commenced the initial public offering of its Class A common stock. Bioventus is offering 7,350,000 shar...

WRAL TechWire - 1 month ago

RESEARCH TRIANGLE PARK - Biotech companies continue to jump in line to join the public markets. Bioventus, a medical device maker whose portfolio includes...

News Observer - 1 month ago

This is the second time North Carolina medical device maker applied to go public via an initial public offering. In 2016, the company rescinded its application citing market conditions.

NASDAQ - 1 month ago

Bioventus, which offers orthobiologics products for musculoskeletal conditions, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. The company had previ...

SEC - 1 month ago

Bioventus, Inc. has filed to go public with an IPO on the NASDAQ.

About BVS

Bioventus focuses on operating as a holding company for Bioventus LLC that operates as a medical device company. It develops and commercializes clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived... [Read more...]

Industry
Medical Devices
IPO Date
Feb 11, 2021
CEO
Kenneth M. Reali
Employees
680
Stock Exchange
NASDAQ
Ticker Symbol
BVS
Full Company Profile

Financial Performance

Financial Statements